Lead Plaintiff Deadline: November 28, 2022
Please Upload related files below
Fill in below.
Looking for more?
: (a) American Depositary Shares pursuant and/or traceable to documents issued in connection with the Company’s initial public offering conducted on or about May 28, 2021; and/or (b) Centessa securities between May 28, 2021 and June 1, 2022
(i) the Company’s product, lixivaptan, was less safe than defendants had represented; (ii) defendants overstated lixivaptan’s clinical and commercial prospects; (iii) another Centessa product, ZF874, was less safe than defendants had represented; (iv) defendants overstated ZF874’s clinical and commercial prospects while downplaying the drug’s safety issues; and (v) as a result, documents issued in connection with Centessa’s initial public offering and the Company’s public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
In order to be included in the lawsuit, you must have incurred a loss on shares of Centessa purchased or acquired during the class period listed above and/or pursuant to the stock offering(s) referenced above.
If you suffered a loss in Centessa during the relevant time frame or pursuant to the relevant offering(s), you have until November 28, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.